INTRODUCTION

Primary malignant renal tumors include a wide range of tumors, among them renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis are the most common. Others include sarcomas, lymphomas and leukemia.

Renal cell carcinoma (RCC) overall accounts for 2% of all adult malignancies. Worldwide, based on probably incomplete figures, about 270000 new cases are diagnosed per year, and about 116 000 patients die per year. It constitutes approximately 85% of all primary malignant renal tumors. Approximately 54,000 new diagnoses of RCC are made each year in the United States, and 13,000 patients die of disease. Nearly 20,000 new cases are detected in the European Union annually.

RCC is primarily a disease of the elderly with typical presentation in the Sixth & Seventh decades of life. There is a male predominance with a ratio of 3:2. The incidence rates are 10–20% higher in African Americans in both men and women. Annual mortality-to-incidence ratio with RCC is significantly higher compared to other urological malignancies making it the most lethal urological malignancy.
As for geographical variation, the rates are low in Asian countries and high in the USA and Canada. The incidence has increased more than 30% over the past two decades. It is generally postulated that the increased incidence rates reflect earlier diagnosis at an earlier stage, largely due to more liberal use of radiological imaging techniques. However, advanced disease has also been diagnosed more frequently and the mortality rate has increased as well.

**METHODS**

From July 2003 to July 2009, data were collected retrospectively from the records of adult patients with primary malignant renal tumors presented to Jordan University Hospital and Al-Jumhory Teaching Hospital, these data include age, sex, anatomical side, presenting symptoms, diagnosis, metastasis if any, therapeutic options, histopathological subtype and tumor stage.

The numbers of patients who had full data and fulfill these criteria were 55 patients. The study was approved by the authorities of the department of surgery in Mosul College of medicine.

**RESULTS**

A total of 55 adults with primary malignant renal tumors presented to us over 6 years, 41 (74.5%) were males and 14 (25.5%) females; of those patients 44 had RCC (80%), 8 patients had TCC of the renal pelvis (14.5%), 2 had sarcomas (3.6%) and one had renal lymphoma (1.8%).

**Regarding those with RCC:** some of the patients characteristics are shown in Table-I. The main presenting symptom was hematuria followed by loin pain and was incidental in 7 only. Constitutional symptoms (Nausea, weight loss, malaise, fatigue, fever and night Sweating) in 6 patients and metastatic symptoms (bone Pain, cough, hemoptysis and shortness of breath) in 2 patients (4.5%) (Table-I). Only 8 /44 (18.2%) patients had palpable abdominal mass.

Ultrasound was the initial diagnostic tool in all patients followed by abdominal computed tomography (CT) scan and chest X-ray. While MRI, chest CT scan and bone isotopes scan were done upon clinical suspicion. Selective angiography only done in few patients.

Metastasis at presentation was noticed in 14/44 (31.8%) of our patients, the most common metastatic site was the lung in 8 /14 (57.1%), Bone in 5/14(35.7%), liver in 4/14 (28.6%), brain in 2/14 (14.2%), adrenals in 2/14 (14.2%) and skin in 1/14 (7.1%).

**Considering the management of those patients:** 36/44 (81.8%) underwent Radical Nephrectomy, among them 6/36 (16.7%) had metastasis (cytoreductive nephrectomy), only one patient had renal vein involvement and one patient had simultaneous solitary lung metastasis resection. An adrenal gland excision was concomitantly performed in 41.7% of the cases when there is extensive renal tumor, upper pole tumor or radiological suspension of adrenal metastasis.

**While the other 8/44 (18.2%) were treated nonsurgically:** 4 of them were treated with targeted therapy (sunitinib), 2 with Interferon-α, one patient treated with Thalidomide and one patient was in terminal stage and only palliative treatment given.

**Regarding histopathology:** conventional clear cell carcinoma was the most common type, The most frequent tumor stage according to the TNM classification system was T2 (Table-II). Positive lymph nodes involvement was found in 6/36 patients (16.7%). Renal biopsy guided by CT. Scan done in 7 patients with metastatic RCC, the other patient had skin nodules over his back proved by skin excisional biopsy to be metastatic RCC.

| Patients Number | 44 |
|----------------|----|
| Male: Female   | 33/11 |
| Age(Years)     | 21-80 Range: Mean:56 |
| Side           | Right 54% Left 46% |
| Localized Disease | 30 (68.2%) |
| Metastatic     | 14 (31.8%) |

**Histopathology**

- Clear Cell Carcinoma: 35 (79.5%)
- Papillary: 5 (11.3%)
- Chromophobe Cells: 2 (4.6%)
- Sarcomatoid: 1 (2.3%)
- Collecting Duct (Bellini): 1 (2.3%)

**Fuhrman nuclear grade**

- I and II: 29 (65.9%)
- III and IV: 15 (34.1%)

**Staging**

- T1: 6 (16.1%)
- T2: 16 (44.5%)
- T3: 9 (25%)
- T4: 5 (13.8%)

**Table-I:** The clinical presentation of patients with renal cell carcinoma.

| Characteristics | Percentage |
|----------------|------------|
| Hematuria      | 39%        |
| Loin pain      | 27%        |
| Constitutional | 14%        |
| Incidental     | 16%        |
| Metastatic     | 4%         |
Two patients had end stage renal disease (ESRD) with acquired renal cystic disease (ARCD) who developed RCC.

As regards patients with TCC of renal pelvis: 7/8 were males and one female, mean Age was 57 years (49-62); all had renal pelvic TCC, the main presenting symptom was hematuria in all patients, intravenous urography (IVU) and CT scan done for all patients, all of them had localized disease and treated with radical Nephro-ureterectomy and bladder cuff removal. Tumor stage was T2 in 5 patients and T1 in 3 patients, tumor grade was well differentiated in 3 patients, moderately differentiated in 4 and poorly differentiated in one patient.

Cystoscopy done for all patients at the same time of the radical Nephro-ureterectomy and showed no bladder growth but within one year 4/8 (50%) of them developed bladder TCC, all were treated with transurethral resection of bladder tumor (TURBT) and 2 of them require further treatment with intravesical immunotherapy.

Two male patients had sarcomas (fibrosarcoma and leiomyosarcoma), treated with radical nephrectomy and proved to have localized disease, one Female Patient presented with left renal mass proved to be renal lymphoma following radical nephrectomy and was referred to oncologist.

DISCUSSION

Renal cancer in general represent 1.6% and 2% of all cancers in Iraq and Jordan respectively, in both Syria and Lebanon renal cancers represent 1.8% for each, renal cancer is the 2nd most common urological tumor in Iraq preceded by bladder cancer only, while in Jordan it is the 3rd, one preceded by prostate and bladder cancers respectively.

RCC usually occur during the 6th or 7th Decade of life, however, in our patients the mean age was 56 Years and we have 3/44 Patients (6.8%) younger than 40 years old (21, 25 and 28 years), all of them were females without family history of renal tumors, in a study by Taccone et al. showed that 7.5% of their RCC series were less than 40 years old.

In our series, the male: female ratio was 3:1 (25% female and 75% male) with a Lower female incidence than the known ratio of 3:2. Another study from Jordan showed that the male to female ratio was 3.4:1 and the mean patient age was 54 years. This is close to our mean age which was 56 years.

The main presenting Symptom was hematuria in 38.6% and loin pain in 27.2%. However in other studies they reported hematuria in 40-60% of patients, flank pain may be seen in up to 40% of patients and is caused by either bleeding within the tumor or invasion of contiguous tissues.

Constitutional symptoms (weight loss, nausea, malaise, fatigue, fever and Night sweating) in 13.6% while 16% only diagnosed incidentally in our patients, however more than 50% of RCCs are now detected incidentally at earlier stages, on the other hand, 26% of cases were diagnosed incidentally in previous Jordanian study and 14% only diagnosed incidentally in a study by Al-Marhoon. 2 of our patients (4.5%) presented with metastatic Symptoms (bone pain, dyspnea and cough).

In our series 31.8% had metastatic disease, however up to 40% of patients in other series still present with extra renal growth or metastases. Among those who present with metastatic disease, 75% have lung metastases, 36% have soft tissue metastases, 20% have bone metastases, 18% have liver metastases, and 8% each have skin and CNS metastases. However, in our series: most common metastatic site was the lung in 8/14 (57.1%), Bone in 5/14 (35.7%), liver in 4/14 (28.6%), brain in 2/14 (14.2%), adrenals in 2/14 (14.2%) and skin in 1/14 (7.1%). Lymph node enlargement reported in 6/36 (16.7%).

Most of our patients (81.8%) underwent Radical Nephrectomy, among them (16.7%) underwent cytoreductive nephrectomy. In another study radical nephrectomy was performed in 91.6% of the patients. Although nephron sparing surgery nowadays represent the state of the art in renal cancer management, but none of our patients was offered a partial nephrectomy due to lack of adequate experience with such operations and technical limitations.

Clear cell carcinoma usually constitutes 70-80% in other series and it accounted for only 55.5% in a Jordanian study, while it represent 79.5% in our series.

Majority of renal tumors are discovered incidentally at earlier stage. However, we still encountered advanced cases which signify either delayed presentation, improper initial assessment causing delayed diagnosis or the limited availability of the modern imaging modalities.

Patients with TCC of renal pelvis: Upper urinary tract urothelial tumors involving the renal pelvis or ureter are relatively uncommon, accounting for about 5% to 7% of all renal tumors. We had a higher incidence of 8/55 (14.5%), usually men generally are about twice as likely to develop upper tract tumors as are women, however in our series we have one female only.
Mean age was 57 years (49-62 years) which is much younger than the reported age range of 75-79 years. All of them presented with gross hematuria, had no metastasis and all were treated by Radical nephro-ureterectomy with bladder cuff removal, however, 4/8 (50%) of patients developed TCC of the bladder within 12 months of the radical Surgery, knowing that all patients had normal cystoscopy done at the time of radical surgery. Those patients were 3 males and one female; all had multifocal TCC in the renal pelvis at the time of radical nephro-ureterectomy, the histopathological examination of the resected bladder tumors showed superficial bladder TCC (Ta -T1) with grade 1-2 differentiation.

Patients with upper tract tumors are at risk for development of bladder recurrence, with an estimated incidence that varies in multiple reports from 15% to 50%. Most of the bladder recurrences occur within 5 years of the development of the upper tract cancer and 82% of them occur during the first two years.

Primary renal sarcomas, in general, are rare tumors and account for up to 3% of all renal malignancies. In our series Two (3.6%) male patients (59 and 61 years old) presented with renal mass, underwent radical nephrectomy and the histopathology report proved the presence of fibrosarcoma and leiomyosarcoma respectively and the latter offered further treatment with chemotherapy. One (1.8%) female patient had renal lymphoma following radical nephrectomy for Incidental Renal mass.

CONCLUSION

In this study there was a trend toward younger age at Diagnosis, especially in females, yet, we have less overall female Incidence. Hematuria and loin pain were the commonest presenting symptoms, we still encountered locally advanced and metastatic disease with a lower rate of incidentally diagnosed tumors which signifies the importance of early consultation and proper assessment of patients with suggestive Symptoms. There are trends toward younger age affection, localized disease and early development of bladder TCC within less than one year following radical surgery in 50% of the patients which indicate the importance of strict surveillance protocol.

Note: No Conflict of Interest.

REFERENCES

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008;127:2893–2917.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
4. Kircali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int. 2001;88:818–824.
5. Wallen EM, Pruthi RS, Joyce GF, Wise M. Urologic Diseases in America Project. Kidney cancer. J Urol. 2007;177(6):2006-2019; discussion 2018-2019.
6. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–1631.
7. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin. 2000;50:57.
8. Chow WH, Devesa SS, Fraumeni Jr JF. Epidemiology of renal cell Carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, Editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins; 2000:1011–1015.
9. WHO, International Agency for Research on Cancer (IARC) GLOBOCAN 2008 http://globocan.iarc.fr/factsheet.asp Accessed on 2/1/2013.
10. Taccon X, Valeri A, Descotes J, Morin V, Sterdel E, Douuet L, et al. Renal Cell Carcinoma in adults 40 years old or less young Age is an Independent Prognostic Factor for Cancer-Specific Survival. Eur Urol. 2007;51:980–987.
11. Ghalayini I, Bani-Hani I. Detection, staging and clinical implications of renal cell carcinoma. Saudi Med J. 2003;24(1):79-83.
12. McDougal WS, Garnick MB. Clinical signs and symptoms of renal Cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Comprehensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott Williams & Wilkins; 2000:1011–1015.
13. Slaton J, Swanson DA. Renal cell carcinoma—diagnosis and Staging. In: Brukowski RM, Novick AC, editors. Renal cell Carcinoma. Totowa (NJ): Humana Press; 2000:111–133.
14. Kirgali Z, O’ bek C. Clinical aspects of renal cell carcinoma. EUA Update Series. 2003;1:189-196.
15. Al-Marhoon MS, Osman AM, Kamal MM, Shokeir AA. Incidental vs symptomatic renal tumors: Survival outcomes. Arab J Urol. 2011(9):17-21.
16. Amin MB, Amin MB, Tamboli P. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol. 2002;26:281–291.
17. Maldazys JD, Dekernion JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1986;136(2):376-379.
18. Hisatami T, Miyao N, Masumori N. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology. 2000;55(5):663-667.
19. Kang CH, Yu TJ, Hsieh HH. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003;98:1620-1626.
20. Mullerad M, Russo P, Golijanin D. Bladder cancer as a prognostic Factor for upper tract transitional cell carcinoma. J Urol. 2004;172:2177–2181.
21. Van der Poel HG, Antonini N, van Tinteren H. Upper urinary tract cancer: Location is correlated with prognosis. Eur Urol. 2005;48:438–444.
22. Matsu Y, Utsunomiya N, Ichikawa K. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology. 2005;65:279–283.
23. Kitajima K, Kaji Y, Morita M, Okuda Y, Sugimura K. Malignant fibrous histiocytoma arising from the renal capsule. Magn Reson Med Sci. 2003;2:199-202.